Jones C, Zhao Z, Barber B, Bagijn M, Corrie P, Saltman D
PRMA Consulting Ltd, Hampshire, GU51 3QT, UK.
Amgen Inc., Thousand Oaks, CA, 91320-1799, USA.
Eur J Cancer Care (Engl). 2015 Nov;24(6):862-6. doi: 10.1111/ecc.12326. Epub 2015 May 18.
With the emergence of new therapies, established patterns of treating advanced melanoma are changing. The aim of this study was to understand how advanced melanoma is treated in clinical practice in Europe following the introduction of ipilimumab and vemurafenib. An online survey was conducted between August and November 2012 with 150 oncologists and dermatologists, from France, Germany, Italy, Spain and the U.K.; respondents reported treating the majority of patients with one or two lines of therapy. For BRAF mutant melanoma, the most frequently used first-line treatments were vemurafenib and dacarbazine. For BRAF wild-type melanoma, the most frequently used first-line treatment was dacarbazine. There was no single preferred agent for the second-line treatment of BRAF mutant or BRAF wild-type disease. Most sequencing from first- to second-line was from conventional dacarbazine to newer agents such as ipilimumab and vemurafenib. The treatment of advanced melanoma is rapidly evolving due to the introduction of new agents. This study presents an early insight into access to the new agents, ipilimumab and vemurafenib, and clinical practice in several European countries.
随着新疗法的出现，晚期黑色素瘤既定的治疗模式正在发生变化。本研究的目的是了解在引入伊匹单抗和维罗非尼后，欧洲临床实践中晚期黑色素瘤是如何治疗的。2012年8月至11月对来自法国、德国、意大利、西班牙和英国的150名肿瘤学家和皮肤科医生进行了一项在线调查；受访者报告称，大多数患者接受一或二线治疗。对于BRAF突变型黑色素瘤，最常用的一线治疗药物是维罗非尼和达卡巴嗪。对于BRAF野生型黑色素瘤，最常用的一线治疗药物是达卡巴嗪。BRAF突变型或BRAF野生型疾病的二线治疗没有单一的首选药物。大多数从一线到二线的序贯治疗是从传统的达卡巴嗪到伊匹单抗和维罗非尼等新型药物。由于新型药物的引入，晚期黑色素瘤的治疗正在迅速演变。本研究对几个欧洲国家获取伊匹单抗和维罗非尼这两种新型药物的情况以及临床实践提供了早期见解。
